Accounts tell us some magic stuff if we take the time to look. Just reviewing BD1 my selection only of main expenses Employee, R&D Patent and Admin items. Go back to 2016 and Zero R&D gave me a start date of 2017 for my interest.See Page 17 of 2016
2017 Page 10 gets into the work . Employee (701,669) R&D (1,089,976) Patent (131,187) and Admin (575,252)
2018 Page 11 Employee (768,598) R&D (770,842) Patent (180,854) and Admin (375,731)
Checked 1/2 yearly reports and found something clearly missing . A liability charge to Non-Current Liabilities or payment for Thermo Fisher assay development program.
Is Thermo Fisher doing it for free or is it the mystery or not so mysterious partner in progress pending outcomes of the assay development program and commercial test validation?
My purely speculative belief is Thermo Fisher is not giving us a freebie. This makes me think we have 106.30B $USD working partner. Thermo Fisher "2015 - 2018 Significant Acquisitions/Divestiture" is interesting . One was Patheon N.V. "Leading contract development and manufacturing organization serving the pharmaceutical and biotechnology sectors" with 1.8b USD revenue at the time of Acquisition.
I could of course be wrong. Before some get upset this has not been clarified by BD1, I think they have already advised us of this. "Corporate update: During the quarter BARD1 continued to explore various corporate and fundraising opportunities to build the Company and advance development and commercialization of its diagnostic assets to grow shareholder value." is in almost every document I linked to in one form or another.
Can anyone see payments to Thermo Fisher assay development program?
If I am correct this might put a smile on holders faces Link "From 2008 through 2017, we helped clients earn 117 new drug application (NDA) approvals. That’s twice as many as any other CMO/CDMO. Partner with Thermo Fisher Scientific and benefit from our depth and breadth of experience, reliability of quality and refinement of processes – are all of which are vital in the final push for regulatory approval and in making the transition to commercial manufacturing.
With industry-leading depth of expertise and resources, responsiveness, flexibility, and dependable quality, Thermo Fisher Scientific teams understand the approval process inside and out. We can work with you to achieve parallel active pharmaceutical ingredient (API) and finished dose development – bringing Right First Time/On-time reliability. Our seasoned experts know exactly what’s required and the pitfalls that lead to costly delays. We consistently deliver high quality in everything we do, and this has earned us the trust of the world’s top 20 pharmaceutical companies, and 18 of the top 20 biotech companies.
Where some may view regulatory inspections as a hurdle, we view them as an impartial measure of excellence. In the past 10 years, our facilities have undergone more than 325 regulatory inspections and 33 pre-approval inspections (PAIs) have been waived by the FDA. We have consistently delivered this level of quality for clients year after year, for more than 10 years."
My Speculation is just that.
